Memphis, TNNCT06777979Now EnrollingIRB Ready

Acute Lymphoblastic Leukemia Clinical Trial in Memphis, TN

Access cutting-edge acute lymphoblastic leukemia treatment through this phase 1 clinical trial at a research site in Memphis. Study-provided care at no cost to qualified participants.

Sponsored by St. Jude Children's Research Hospital

Quick Self-Assessment

See if you qualify for this Memphis location

Preparing your pre-screening questions…

Expert Care in Memphis

Access acute lymphoblastic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute lymphoblastic leukemia treatment provided free

Apply for This Memphis Location

Check if you qualify for this acute lymphoblastic leukemia clinical trial in Memphis, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Memphis

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Memphis site if eligible
  4. 4Begin participation

About This Acute Lymphoblastic Leukemia Study in Memphis

This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in patients ≤ 21 years of age with recurrent/refractory CD19- and/or CD22-positive leukemia. Secondary Objective: To evaluate the anti-leukemic activity of CD19-CD22-CAR T cells.

Sponsor: St. Jude Children's Research Hospital

Who Can Participate

Inclusion Criteria

Age \<21 years old
Relapsed/refractory CD19- and/or CD22-positive acute leukemia defined as: \*CD19 and/or CD22-positivity confirmed within 2 months and after receipt of any CD19 or CD22-directed therapy
Second or greater relapse
Any relapse after allogeneic HCT
Refractory disease (primary or in relapse) despite therapy designed to induce remission
Estimated life expectancy of \> 12 weeks
Karnofsky or Lansky (age-dependent) performance score ≥50 (Appendix A)
For females of childbearing age:
Not lactating with intent to breastfeed
Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment

Exclusion Criteria

Known primary immunodeficiency
Known HIV positivity
Known contraindication to receiving protocol defined lymphodepleting
chemotherapy regimen
History of hypersensitivity reaction to murine protein-containing products Treatment Eligibility Inclusion Criteria:
Age \< 21 years old
Detectable disease in the bone marrow
Estimated life expectancy of \> 8 weeks
Karnofsky or Lansky (age-dependent) performance score \> 50 (Appendix A)
Adequate cardiac function defined as left ventricular ejection fraction \>40%, or shortening fraction \> 25%
EKG without evidence of clinically significant arrhythmia
Adequate renal function defined as creatinine clearance or radioisotope GFR \>50 mL/min/1.73m2 (GFR \>40 mL/min/1.73m2 if \<2 years of age)
Adequate pulmonary function defined as forced vital capacity (FVC) \>50% of predicted value; or pulse oximetry \>92% on room air
Total bilirubin \< 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5 times the upper limit of normal for age
Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
Prior to planned CAR T cell infusion, patients with a history of prior allogeneicHCT must be at least 3 months from HCT, have no evidence of acute GVHD, and have not received a donor lymphocyte infusion (DLI) within the 28 daysprior to planned infusion
For females of childbearing age:
Not lactating with intent to breastfeed
Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
If sexually active, agreement to use birth control until 3 months after T cell infusion. Male partners should use a condom. Exclusion Criteria:
Known primary immunodeficiency
Known HIV positivity
Known contraindication to receiving protocol defined lymphodepleting
chemotherapy regimen
History of hypersensitivity reactions to murine protein-containing products
Severe, uncontrolled bacterial, viral or fungal infection
Active CNS-3 disease
Evidence of active, uncontrolled neurologic disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT06777979) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphoblastic Leukemia Treatment Options in Memphis, TN

If you're searching for acute lymphoblastic leukemia treatment options in Memphis, TN, this clinical trial (NCT06777979) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Memphis, TN

See all leukemia clinical trials recruiting in Memphis — not just this study.

Browse Leukemia Trials in Memphis →

Browse More Trials by Condition

Leukemia TrialsB-Cell Acute Lymphoblastic Leukemia TrialsHeart Attack TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Memphis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Memphis, TN